Objectives: We evaluated the clinical outcomes of elderly patients who underwent orbital atherectomy for the treatment of severe coronary artery calcification (CAC) prior to stenting. Background: Percutaneous coronary intervention (PCI) of severe CAC is associated with worse clinical outcomes including death, myocardial infarction (MI), and target vessel revascularization (TVR). The elderly represents a high-risk group of patients, often have more comorbid conditions, and have worse outcomes after PCI compared to younger patients. Clinical trials and a large multicenter registry have demonstrated the safety and efficacy of orbital atherectomy for the treatment of severe CAC. Clinical outcomes of elderly patients who undergo orbital atherectomy are unknown. Methods: Of the 458 patients, 229 were !75 years old (elderly) and 229 were <75 years old (younger). The primary endpoint was rate of 30-day major adverse cardiac and cerebrovascular events (MACCE), comprised of cardiac death, MI, TVR, and stroke. Results: The primary endpoint was similar in the elderly and younger groups (2.2% vs. 2.2%, P ¼ 1), as were the individual endpoints of death (2.2% vs. 0.4%, P ¼ 0.1), MI (0.9% vs. 1.3%, P ¼ 0.65), TVR (0% vs. 0%, P ¼ 1), and stroke (0% vs. 0.4%, P ¼ 0.32). The rates of angiographic complications and stent thrombosis were similarly low in both groups. Conclusions: The elderly represented a sizeable number of patients who underwent orbital atherectomy. It is a safe and effective treatment strategy for elderly patients with severe CAC as the clinical outcomes were similar to their younger counterparts. A randomized trial should further clarify the role of orbital atherectomy in these patients. (J Interven Cardiol 2017;30:134-138) 
Introduction
Percutaneous coronary intervention (PCI) of severe coronary artery calcification (CAC) is more technically challenging as advancing balloons and stents to the lesion and achieving optimal stent expansion may be difficult. 1 Repetitive, prolonged, high-pressure balloon inflations to remedy a suboptimally expanded stent may result in ischemia, dissection, or perforation. 2 The calcified lesion can damage the stent and polymer during aggressive attempts to advance the stent, resulting in a higher restenosis rate. These factors may explain the poor outcomes including death, myocardial infarction (MI), target vessel revascularization (TVR), and stent thrombosis associated with PCI of severe CAC. 3 Over 43 million of the 322 million people in the United States are older than 65 years of age, and by 2050, this population is expected to double to 83.7 million. 4 Severe CAC is detected in approximately 38% during angiography and 73% when intravascular ultrasound is used. 5 The elderly represents a high-risk group of patients as they often have more comorbid conditions, increased frailty, multi-vessel disease, and Disclosure statement: Michael Lee, Evan Shlofmitz, and Richard Shlofmitz have consulting agreements with Cardiovascular Systems, Inc. Gentian Lluri has no conflicts of interest.more complex coronary anatomy including tortuosity and severe CAC, leading to higher adverse clinical outcomes including higher mortality rates after PCI. [6] [7] [8] Age was an independent predictor of major adverse cardiac events and mortality in patients undergoing PCI. 8, 9 Age also features prominently in risk stratification scores in predicting adverse clinical events after PCI. [10] [11] [12] Our multicenter registry reported low rates of angiographic and adverse clinical events in 458 patients with severe CAC who underwent orbital atherectomy followed by stenting. 13 Outcomes of elderly patients who underwent orbital atherectomy have not been previously described. In this retrospective analysis, we evaluated the impact of age on ischemic complications in patients who underwent orbital atherectomy.
Methods
Study Population. Our retrospective analysis included 458 consecutive patients with severe CAC who were treated with orbital atherectomy between October 2013 and December 2015 at 3 centers (UCLA Medical Center, Los Angeles, CA, St. Francis Hospital, Roslyn, NY, and Northwell Health, Manhasset, NY). Patients were stratified by age: !75 years old (elderly) and <75 years old (younger). Severe CAC was defined by the presence of radio-opacities of the vessel wall on fluoroscopy. 13 The institutional review board at each center approved the review of the data.
Device Description. The coronary orbital atherectomy device (Cardiovascular Systems, Inc.
[CSI], St Paul, MN) has been previously described.
14 A 0.014 00 ViperWire (CSI) is advanced across the lesion into the distal arterial bed. The ViperSlide (CSI) lubricant infuses continuously through the drive shaft while the device is advanced over the ViperWire to the lesion and during ablation to minimize heat and friction. The 1.25 mm crown coated with 30-micron diamonds is mounted eccentrically so that it expands laterally while rotating due to centrifugal force.
Procedure and Adjunctive Pharmacotherapy. Percutaneous coronary intervention was performed with standard technique. The decision to insert a transvenous pacemaker and hemodynamic support device was left to the discretion of the operator. Orbital atherectomy was initially activated at low speed (80,000 rpm) in all cases and escalated to high speed (120,000 rpm) if the reference vessel diameter was at least 3 mm. Each pass was limited to 20 seconds. It was the operator's discretion to predilate the lesion and use intravascular imaging (intravascular ultrasound or optical coherence tomography) as well as choice of the stent type, antithrombotic agent, and antiplatelet regimen.
Endpoints. The primary endpoint was 30-day major adverse cardiac and cerebrovascular events (MACCE), as defined as all-cause mortality, MI, TVR, and stroke. Myocardial infarction was defined as recurrent symptoms with new ST-segment elevation or re-elevation of cardiac markers >2Â the upper limit of normal. Target vessel revascularization was defined as a repeat revascularization of the target vessel because of restenosis within the stent. The Academic Research Consortium definition of stent thrombosis was used.
14 A dedicated PCI database was established to record demographic, angiographic, and procedural data as well as clinical outcomes were collected from medical records.
Statistical Analysis. Continuous variables are expressed as mean and standard deviation and compared using Student t-test. Categorical variables are expressed as percentages and compared using chi square test. A P-value <0.05 was considered statistically significant. Statistical analysis was performed with GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA).
Results
Baseline Demographic Characteristics. Of the 458 patients in our study, 229 (50%) were elderly and 229 (50%) were younger ( Table 1 ). The elderly group had a lower prevalence of diabetes mellitus (35.8% vs. 48.59%, P ¼ 0.006) but a higher prevalence of chronic kidney disease (serum creatinine !1.5 mg/dl) (23.4% vs.15.3%) and presentation with MI (14.4% vs. 7.9%, P ¼ 0.03). The procedural data are presented in Table  2 . The total stent length was lower in the elderly group (40.8 AE 1.7 mm vs. 46.3 AE 2.1, P ¼ 0.04). Less contrast was used in the elderly patients (177.4 AE 5.4 ml vs. 197.9 AE 6.6 ml, P ¼ 0.02).
Procedural Results. Angiographic complications were also low and similar in the elderly and younger patients: perforation (0.6% vs. 0.4%, P ¼ 0.6), dissection (0.4% vs. 1.3%, P ¼ 0.3), and no reflow (0.4% vs. 0.9%, P ¼ 0.3) ( Table 3) .
30-Day Clinical Outcomes.
The primary end point of 30-day MACCE was identical in the elderly and younger patients (2.2% vs. 2.2%, P ¼ 1) (Table 4) . There were no differences in 30-day rates of death (2.2% vs. 0.4%, P ¼ 0.1), MI (0.9% vs. 1.3%, P ¼ 0.7), TVR (0% vs. 0%, P ¼ 1), and stroke (0% vs. 0.4%, P ¼ 0.3). Stent thrombosis (0.9% vs. 0.9%, P ¼ 1) was identical in both groups. The causes of death are presented in Table 5 .
Discussion
In the first analysis of real-world patients who underwent orbital atherectomy, the elderly represented a sizeable number of those who underwent orbital atherectomy. Orbital atherectomy appears to be a safe and effective treatment strategy for elderly patients with severe CAC as the clinical outcomes were similar to their younger counterparts.
Lesion preparation of severely calcified coronary plaque is a crucial step to improve angiographic and procedural success rates and decrease periprocedural complications. The fastest growing age group in the United State is the elderly. 15 Elderly patients are particularly predisposed to developing calcified plaques, have worse baseline clinical risk factors including worse left ventricular function, and are turned down for surgical and percutaneous revascularization more frequently than younger patients. 12, 16, 17 The 30-day MACCE rate was 2.2% in elderly patients and was identical to the younger patients, even though the elderly group had nearly twice the number of patients who presented with MI. The rates of MI, TVR, and stroke were also very low. Angiographic complications were also low and similar compared to the younger patients.
Orbital atherectomy is the first new technology for plaque modification of severely calcified coronary artery lesions in the last 30 years. 18 There are no Values are n (%) or mean AE SEM. Values are n (%) or mean AE SEM. published data on outcomes in elderly patients with severe CAC who underwent orbital atherectomy. Prior to the introduction of orbital atherectomy, rotational atherectomy was the most commonly used atherectomy device for the treatment of severe CAC. However, data on outcomes in elderly patients are limited. A single-center cohort analysis of 26 octogenarians reported a 2-year survival rate of 78% after rotational atherectomy. 19 A study of 13 patients who were over 80 years of age and underwent rotational atherectomy of a calcified left main artery reported similar outcomes compared with 29 patients who did not undergo atherectomy. 20 The only study reporting clinical outcomes in the elderly who underwent orbital atherectomy was with patients with peripheral arterial disease. In the CONFIRM registry, elderly patients who underwent orbital atherectomy for severe peripheral arterial disease had similar outcomes despite having worse baseline symptoms and lesion characteristics compared to younger patients. 21 Several features of orbital atherectomy may make it preferable compared to rotational atherectomy, especially in the elderly. Since the device utilizes an eccentrically mounted crown to modify calcified plaque, it can potentially minimize harm to compliant tissue while preventing the possibility of dissection. In a large diameter vessel with severe calcified stenosis, a step-wise escalation strategy starting with a 1.25 mm rotational atherectomy burr increases procedure time, radiation, and contrast. However, starting with a large burr (!1.75 mm) may increase the risk of dissection and distal embolization. Larger burrs require !7 French guiding catheters whereas orbital atherectomy can be performed with a 6 French guiding catheter. The orbital atherectomy crown is 1.25 mm in diameter and achieves a larger lumen size by increasing the speed from low to high. Orbital atherectomy liberates particles that are generally smaller than those with rotational atherectomy (<2 mm compared with 5-10 mm) which may lead to less distal embolization. Given the higher risk nature of elderly patients, this makes orbital atherectomy an attractive option in this cohort who may not tolerate perturbations in coronary flow. However, a randomized Values are n (%). trial comparing orbital to rotational atherectomy in which a 1.25 mm burr is initially activated at 140,000 rpm to minimize the risk of dissection and distal embolization is needed to determine the ideal atherectomy device for severe CAC. 22 
Study Limitations
This is a retrospective, multicenter study, and thus subject to the limitations inherent to such type of analysis. It was a single arm study which lacked a comparator group that underwent rotational atherectomy or did not undergo atherectomy. The duration of follow-up was short. Longer-term follow-up is needed to assess the durability of orbital atherectomy in the elderly. Differences in baseline characteristics could have affected clinical outcomes between the 2 groups.
Conclusions
Elderly patients represented half of the patients in our multicenter registry who underwent orbital atherectomy. Elderly patients who underwent orbital atherectomy had low adverse clinical events that were similar to the younger patients. Orbital atherectomy appears to be a reasonable treatment option for elderly patients with severe CAC given the safety and efficacy of this technology. A randomized trial with long-term follow-up is needed to identify the optimal treatment for elderly patients with severe CAC.
